Ovid Therapeutics (OVID) Stock: Buy, Sell, or Hold?
OVID - Ovid Therapeutics Inc. Common Stock
$2.16
-0.21 (-8.86%)
▼
5d:
+0.47%
30d:
-13.43%
90d:
-8.09%
HOLD
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 11, 2026
17d
Get Alerted When OVID Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: OVID shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: OVID shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: OVID is currently trading at $2.16, which is considered oversold relative to its 30-day fair value range of $2.26 to $2.63.
Technical Outlook: Technically, OVID is in a strong uptrend. Immediate support is located at $2.09, while resistance sits at $2.65. Short-term momentum is weak, with the stock down 8.9% recently.
Market Sentiment: OVID scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.00 (+177.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, OVID is in a strong uptrend. Immediate support is located at $2.09, while resistance sits at $2.65. Short-term momentum is weak, with the stock down 8.9% recently.
Market Sentiment: OVID scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.00 (+177.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.26 -
$2.63
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.9%)
- BULLISH: Trading 177.8% below Wall St target ($6.00)
Trading Range Analysis
30-Day Trading Range
$2.26 -
$2.63
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.09
Resistance Level
$2.65
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.89
Wall Street Target
$6.00
(+177.8%)
Revenue Growth (YoY)
-88.3%
Share & Embed Analysis
Last updated: October 24, 2026 9:11 AM ET
Data refreshes hourly during market hours. Next update: 10:11 AM
Data refreshes hourly during market hours. Next update: 10:11 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OVID showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
24 analysts |
$258 | 61 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 50 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$72 | 48 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 43 HOLD |
|
SNDX
Syndax Pharmaceuticals I… |
STRONG BUY
12 analysts |
$37 | 59 HOLD |
